Merck has announced the acquisition of Germany-based, mRNA contract development and manufacturing organisation (CDMO) AmpTec.
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
Merck CEO and executive board chairman Stefan Oschmann said: “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases.
“By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.”
Merck’s Life Science business sector’s SAFC portfolio includes lipids, which serve as major components for mRNA therapeutics formulation including for Covid-19 vaccines.
The company is partnering with over 50 vaccine manufacturers to aid in Covid-19 vaccine, treatment and service development and production efforts.
Another vital component of mRNA manufacturing is PCR technology. AmpTec utilises a distinguished PCR-based technology for producing mRNA.
As compared to others, PCR-based manufacturing technology has benefits such as homogeneity, purity, activity and flexibility, increased quality, better performance, as well as adaptable capping options to reach specific performance needs.
Apart from its specialisation in mRNA technology, AmpTec has a diagnostics business focused on making customised long RNAs and DNAs for in vitro diagnostics, which will complement existing Merck portfolio.
AmpTec managing directors and founders Guido Krupp and Peter Scheinert said: “AmpTec’s more than 40 employees are thrilled to join Merck and are confident that our PCR-based technology and combined expertise will allow us to offer customers innovative technologies, products and services to help advance life-enhancing therapeutics.”
Financial terms of the deal remain undivulged.
Last November, Merck signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.
by Pharmaceutical-Technology.com
Source: pharmaceutical-technology.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
